LOGIN  |  REGISTER
Cue Biopharma
Amneal Pharmaceuticals

Sonida Senior Living Announces Date of Second Quarter 2024 Earnings Release and Conference Call

August 05, 2024 | Last Trade: US$23.09 0.78 -3.27

DALLAS / Aug 05, 2024 / Business Wire / Sonida Senior Living, Inc. (“Sonida” or “the Company”) (NYSE: SNDA), a leading operator, owner and investor in communities and services for seniors, today announced that it will issue its second quarter 2024 earnings results before the market opens for trading on Monday, August 12, 2024. The Company will host a conference call and webcast to review its financial performance and operating results on Monday, August 12, 2024, at 11:00 a.m. Eastern Time.

Please visit the Investor Relations website to view the earnings release before the conference call.

The participant toll-free dial-in number for the conference call is (877) 407-0989 (no passcode required). All phone participants are asked to dial in 10 minutes prior to the start of the call to ensure connectivity.

The live webcast of the earnings conference call can be accessed here. A replay of the webcast will be available through the same link following the conference call.

The conference call will be recorded and available for replay starting August 13, 2024, through August 26, 2024. To access the conference call replay, call 877-660-6853, passcode 13743708.

About Sonida Senior Living

Dallas, Texas-based Sonida Senior Living, Inc. is a leading owner, operator and investor in independent living, assisted living and memory care communities and services for senior adults. The Company provides compassionate resident-centric services and care as well as engaging programming to the 82 senior housing communities it operates. Sonida communities are located across 20 states and have an aggregate capacity of approximately 9,000 residents, including 70 communities which the Company owns (8 through joint venture investments) and 12 communities that the Company third-party manages.

For more information, visit www.sonidaseniorliving.com or connect with the Company on Facebook, Twitter or LinkedIn.

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page